BioMarin Clears Path For Pompe Treatment After Knocking Out Genzyme Patents
This article was originally published in The Pink Sheet Daily
Executive Summary
Genzyme’s Myozyme patents invalid for being obvious, Patent Trial and Appeal Board finds in inter partes review.